205 related articles for article (PubMed ID: 29855303)
1. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?
Tang J; Gui C; Qiu S; Wang M
World J Surg Oncol; 2018 May; 16(1):100. PubMed ID: 29855303
[TBL] [Abstract][Full Text] [Related]
2. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance.
Zhou Y; Jiang HG; Lu N; Lu BH; Chen ZH
Asian Pac J Cancer Prev; 2015; 16(4):1605-8. PubMed ID: 25743839
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma.
Ernaga-Lorea A; Hernández-Morhain MC; Anda-Apiñániz E; Pineda-Arribas JJ; Migueliz-Bermejo I; Eguílaz-Esparza N; Irigaray-Echarri A
Clin Transl Oncol; 2018 Jun; 20(6):740-744. PubMed ID: 29071517
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Pathological Characteristics of Patients With Papillary Thyroid Carcinoma Coexisting With Hashimoto's Thyroiditis: A Retrospective Cohort Study.
Yang Y; Liu J; Shi X; Wang M
Cancer Control; 2023; 30():10732748231199647. PubMed ID: 37643366
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
6. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
7. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
8. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
Dai L; Wang Y; Chen L; Zheng J; Li J; Wu X
World J Surg Oncol; 2017 Jan; 15(1):11. PubMed ID: 28061868
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients.
Kim KJ; Kim SM; Lee YS; Chung WY; Chang HS; Park CS
Ann Surg Oncol; 2015 Jan; 22(1):125-31. PubMed ID: 25092159
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma.
Qian Y; Pan Z; Guo Z; Ge X; Zheng G; Cao J; Huang P; Zhu X; Zhu X; Wen Q; Ge M
Biomed Res Int; 2019; 2019():1791065. PubMed ID: 31828091
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma.
Hsueh C; Lin JD; Wu IC; Chao TC; Yu JS; Liou MJ; Yeh CJ
J Surg Oncol; 2011 Apr; 103(5):395-9. PubMed ID: 21400522
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological Significance of Minimal Extrathyroid Extension in Solitary Papillary Thyroid Carcinomas.
Woo CG; Sung CO; Choi YM; Kim WG; Kim TY; Shong YK; Kim WB; Hong SJ; Song DE
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S728-33. PubMed ID: 26077913
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor α/β Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients.
Yi JW; Kim SJ; Kim JK; Seong CY; Yu HW; Chai YJ; Choi JY; Lee KE
Ann Surg Oncol; 2017 Nov; 24(12):3754-3762. PubMed ID: 28124274
[TBL] [Abstract][Full Text] [Related]
14. Is Male Gender a Prognostic Factor for Papillary Thyroid Microcarcinoma?
Lee YH; Lee YM; Sung TY; Yoon JH; Song DE; Kim TY; Baek JH; Ryu JS; Chung KW; Hong SJ
Ann Surg Oncol; 2017 Jul; 24(7):1958-1964. PubMed ID: 28130621
[TBL] [Abstract][Full Text] [Related]
15. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
16. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma.
Karatzas T; Vasileiadis I; Kapetanakis S; Karakostas E; Chrousos G; Kouraklis G
Am J Surg; 2013 Oct; 206(4):586-93. PubMed ID: 23790258
[TBL] [Abstract][Full Text] [Related]
17. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.
Song Q; Wang D; Lou Y; Li C; Fang C; He X; Li J
Diagn Pathol; 2011 Dec; 6():126. PubMed ID: 22188859
[TBL] [Abstract][Full Text] [Related]
19. The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma.
Song E; Oh HS; Jeon MJ; Chung KW; Hong SJ; Ryu JS; Baek JH; Lee JH; Kim WG; Kim WB; Shong YK; Kim TY
Int J Cancer; 2019 Mar; 144(6):1414-1420. PubMed ID: 30357831
[TBL] [Abstract][Full Text] [Related]
20. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
